Schistosomiasis is a disease caused by parasitic trematode worms (schistosomes) that
currently affects 200 million people living in tropical and subtropical environments. It is a …

The chemotherapy of schistosomiasis has improved greatly in the last few decades. There
are three drugs available: metrifonate (active against Schistosoma haematobium) …

Schistosomiasis affects 200 million individuals in underdeveloped and developing regions
and is a growing concern for travelers worldwide. There has been evidence of resistance to …

The authors welcome the publication of a special issue in Parasitology pertaining to the
control of schistosomiasis in Africa. In this editorial, we summarize the key features of the …

Neglected tropical diseases (NTDs) affect millions of people in different geographic regions,
especially the poorest and most vulnerable. Currently NTDs are prevalent in 149 countries …

Schistosomiasis is a chronic and debilitating disease that is caused by parasitic trematode
worms (schistosomes). It continues to threaten millions of people, particularly the rural poor …

In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an
international meeting at the Wellcome Collection in London to explore the current clinical …

No major changes have occurred during the past 20 years regarding the therapeutic tools
available to the clinician for the treatment of schistosomiasis. If anything, the two drugs …

The major antischistosomal drugs that have been or still are in use against infections with
schistosomes are considered here together with some compounds that have not been in …

The current approach of morbidity control of schistosomiasis, a helminth disease of poverty
with considerable public health and socioeconomic impact, is based on preventive …